• Publications
  • Influence
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also ofExpand
  • 752
  • 35
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This EuropeanExpand
  • 641
  • 26
  • PDF
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepaticExpand
  • 551
  • 22
  • PDF
Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease
The expansion of a polyglutamine tract in the ubiquitously expressed huntingtin protein causes Huntington's disease (HD), a dominantly inherited neurodegenerative disease. We show that the activityExpand
  • 233
  • 16
  • PDF
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretinExpand
  • 138
  • 12
Risk for myopathy with statin therapy in high-risk patients.
Emerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) offer important benefits for the large population of individuals at high risk forExpand
  • 442
  • 11
  • PDF
Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport
Many studies have pinpointed the significant contribution of liver‐mediated drug metabolism and transport to the complexity of drug‐induced liver injury (DILI). Phase I cytochrome P450 (CYP450)Expand
  • 75
  • 10
Pharmacology of competitive inhibitors of HMG-CoA reductase.
  • 250
  • 9
Virtual screening approach for the identification of new Rac1 inhibitors.
Rac1 protein is implicated in several events of atherosclerotic plaque development and represents a new potential pharmacological target for cardiovascular diseases. In this paper we describe aExpand
  • 84
  • 7
Non-lipid-related effects of statins
The beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events have generally been attributed to their hypocholesterolaemic properties.Expand
  • 256
  • 6